Showing results (21-30 of 60) with videos related to
Sort By:
Pageof 6
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|December 25, 2022
Assessing the Effects of Modern Renoprotective Agents in Preventing Progression of Renal Composite Outcomes in Patients with Type 2 Diabetes: A Network Meta-analysisSamit Ghosal, Binayak SinhaScientific Reports|September 26, 2020
Assessing the need for pioglitazone in the treatment of patients with type 2 diabetes: a meta-analysis of its risks and benefits from prospective trialsBinayak Sinha, Samit GhosalDiabetes Research and Clinical Practice|February 23, 2019
Meta-analyses of the effects of DPP-4 inhibitors, SGLT2 inhibitors and GLP1 receptor analogues on cardiovascular death, myocardial infarction, stroke and hospitalization for heart failureBinayak Sinha, Samit GhosalDiabetes & Metabolic Syndrome|January 3, 2017
Secondary cvd prevention-Lipid modification strategies: A critical analysisSamit Ghosal, Binayak SinhaJournal of Diabetes Research|December 10, 2015
Gliptins and Cardiovascular Outcomes: A Comparative and Critical Analysis after TECOSSamit Ghosal, Binayak SinhaThe Journal of the Association of Physicians of India|August 24, 2017
Consensus on Bridges for Barriers to Insulin TherapySanjay Kalra, Samit Ghosal, Parag ShahScientific Reports|November 12, 2021
A meta-analysis of the effects of glucagon-like-peptide 1 receptor agonist (GLP1-RA) in nonalcoholic fatty liver disease (NAFLD) with type 2 diabetes (T2D)Samit Ghosal, Debasis Datta, Binayak SinhaJGH Open : an Open Access Journal of Gastroenterology and Hepatology|February 8, 2021
Meta-analysis of the effects of sodium glucose cotransporter 2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetesBinayak Sinha, Debasis Datta, Samit GhosalWorld Journal of Diabetes|November 1, 2016
Glucagon-like peptide-1 receptor agonists favorably address all components of metabolic syndromeSanjay Chatterjee, Samit Ghosal, Saurav ChatterjeeJournal of Clinical Medicine|October 28, 2023
The Renal Composite Benefit of Sodium Glucose Co-Transporter 2 Inhibitors Should Ideally Be Assessed Based on a Standardised Definition: A Meta-Analysis of Randomised Controlled TrialsSamit Ghosal, Shamita Ghosal, Anuradha GhosalPageof 6